• Screening for Nitrosamines in Pharmaceutical Products

Chromatography

Screening for Nitrosamines in Pharmaceutical Products

Feb 24 2020

Nitrosamine are carcinogenic compounds so need to be monitored to ensure unsafe levels are not found in consumer products.  Due to unsafe levels being found in a number of pharmaceutical products the EMA (European Medicines Agency) is requiring pharmaceutical companies to complete and submit a risk assessment by 26th March.  This means many pharmaceutical manufacturers will potentially need to screen their products for nitrosamine content.

The Ellutia 800 Series TEA is perfectly suited to nitrosamine detection thanks to is selectivity and sensitivity for Nitroso compounds. For testing of pharmaceutical drugs, The 800 Series TEA can be interfaced to a chemical stripping system that allows for rapid testing of ATNC (Apparent Total N-nitrosamine content).  This quickly gives an accurate result for the total nitrosamine content of a sample showing both volatile and non-volatile components. 

Any positive sample can then be further analysed by an 800 Series TEA interfaced to a GC where volatile nitrosamines such as NDMA (N-Nitrosodimethylamine) can be separated and quantified.

More information online


Digital Edition

Labmate UK & Ireland 49.2 - March 2024

March 2024

In This Edition Articles - Choosing the right LIMS for your lab: Four key considerations - Pay increases to continue but staff focus on security and training - Building a global culture of...

View all digital editions

Events

Making Pharmaceuticals

Mar 26 2024 Milan, Italy

FORUM LABO LYON

Mar 27 2024 Lyon, France

Microbiology Society Annual Conference 2024

Apr 08 2024 Edinburgh 2024

analytica 2024

Apr 09 2024 Munich, Germany

ChemBio Finland 2024

Apr 10 2024 Helsinki, Finland

View all events